| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Thromboxane B2 itself is considered biologically inert but serves as the stable degradation product of thromboxane A2. Its primary "target" in research contexts is as a measurable surrogate for TXA2 activity. TXA2, the active parent compound, exerts its effects by binding to thromboxane prostanoid (TP) receptors, which are G protein-coupled receptors with seven transmembrane domains linked to phospholipase C activation via G proteins, leading to platelet aggregation and vasoconstriction. TXB2 is measured as an indicator of TXA2 production.
|
|---|---|
| ln Vitro |
In vitro, Thromboxane B2 is used as a stable marker of thromboxane A2 production in platelet aggregation studies, inflammatory responses, and cardiovascular research. TXA2 (the active molecule) induces arterial contraction and platelet aggregation by stimulating TP-α receptors. TXB2 itself does not possess significant biological activity but is the primary analyte measured in ELISA and other immunoassays to quantify thromboxane production in biological samples such as plasma, serum, and urine.
|
| ln Vivo |
In vivo, Thromboxane B2 levels are measured in biological fluids as a biomarker of TXA2 production and platelet activation. Elevated TXB2 levels are associated with cardiovascular diseases, thrombosis, inflammation, and anaphylaxis. In animal models, TXB2 measurements are used to assess platelet function, thrombosis risk, and the efficacy of anti-platelet therapies. TXB2 plays a crucial role in various physiological and pathological processes, including hemostasis, inflammation, and cardiovascular diseases.
|
| Enzyme Assay |
Enzyme-linked immunosorbent assay (ELISA) is the standard method for measuring Thromboxane B2 in biological samples. Competitive ELISA formats are used where TXB2 in the sample competes with enzyme-labeled TXB2 for binding to a limited amount of anti-TXB2 antibody. The assay involves coating plates with anti-TXB2 antibody, adding samples and TXB2-conjugate, washing, adding substrate, and measuring colorimetric signal. Alternatively, LC-MS/MS methods are used for quantitative analysis of TXB2 in research and clinical settings. TXB2 is also used as a standard in these assays.
|
| Cell Assay |
Thromboxane B2 cellular assays typically involve stimulation of platelets or other cells to produce TXA2, which is then measured as TXB2. Platelets are isolated from whole blood and stimulated with agonists such as collagen, ADP, arachidonic acid, or thrombin. After stimulation, samples are centrifuged, and the supernatant is collected for TXB2 measurement by ELISA. Inhibition of TXA2 production by pharmacological agents (e.g., aspirin, COX inhibitors, TP receptor antagonists) is assessed by measuring TXB2 levels in stimulated platelet supernatants. TXB2 serves as the primary readout for platelet function and thromboxane synthesis assays.
|
| Animal Protocol |
In vivo animal experiments involving Thromboxane B2 typically measure TXB2 levels as a biomarker of platelet activation and thromboxane synthesis. Animal models of thrombosis, cardiovascular disease, inflammation, or anaphylaxis are used. Blood samples are collected at various time points, and plasma or serum is prepared. TXB2 is extracted and quantified by ELISA or LC-MS/MS. In some models, TXB2 urinary metabolites (e.g., 11-dehydro-TXB2) are measured as a more stable and integrated marker of systemic TXA2 production. Pharmacological interventions are evaluated based on their ability to reduce TXB2 levels.
|
| ADME/Pharmacokinetics |
As a stable metabolite, Thromboxane B2 itself does not have significant pharmacokinetic properties as a drug. TXA2, the parent compound, has an extremely short half-life of approximately 30 seconds, rapidly hydrolyzing non-enzymatically to TXB2. TXB2 is cleared from the circulation primarily by renal excretion and hepatic metabolism. Plasma TXB2 levels reflect recent TXA2 production. In research settings, TXB2 is measured as a pharmacokinetic biomarker for TXA2 synthesis inhibition by drugs such as aspirin (irreversible COX-1 inhibition) or thromboxane synthase inhibitors.
|
| Toxicity/Toxicokinetics |
Thromboxane B2 itself is not used as a therapeutic drug and has no direct toxicity. However, elevated TXA2 (measured as TXB2) is associated with pathological conditions including thrombosis, myocardial infarction, stroke, and asthma. TXA2-induced vasoconstriction and platelet aggregation contribute to ischemic events. In toxicity studies, TXB2 is measured as a biomarker of drug-induced platelet activation or cardiovascular toxicity. Compounds that increase TXA2 production may have pro-thrombotic potential, while TXA2 synthesis inhibition is generally considered protective against cardiovascular events.
|
| Additional Infomation |
Thromboxane B2 is a type of thromboxane B compound, chemically named (5Z,13E)-thromboxane-5,13-diene-1-acid, with hydroxyl groups substituted at positions 9, 11, and 15. It is a metabolite in both humans and mice. It is the conjugate acid of thromboxane B2(1-). Thromboxane B2 has been reported to exist in the Chinese honeybee (Apis cerana), and relevant data are available. Thromboxane B2 is an eicosate and a bioactive metabolite of thromboxane A2. Thromboxane B2 is released during allergic reactions. Due to the short half-life of thromboxane A2, thromboxane B2 levels can be used to indirectly measure thromboxane A2 production. Thromboxane A2 is a stable, physiologically active compound formed in vivo from prostaglandin intraperoxides. It plays an important role in platelet release reactions (the release of ADP and serotonin).
Thromboxane B2 (CAS# 54397-85-2) has the molecular formula C₂₀H₃₄O₆ and a molecular weight of 370.48. It is a prostaglandin derivative released during anaphylaxis and induces arterial contraction and platelet aggregation via TXA2 activity. TXB2 is the stable, biologically inert metabolite formed from the non-enzymatic hydrolysis of TXA2, which has a half-life of about 30 seconds. TXB2 plays a crucial role in hemostasis, inflammation, and cardiovascular disease research. It is widely used as a diagnostic biomarker for thromboxane synthesis. TXB2 is not approved as a therapeutic agent but is an essential research tool. |
| Molecular Formula |
C20H34O6
|
|---|---|
| Molecular Weight |
370.48
|
| Exact Mass |
370.235
|
| CAS # |
54397-85-2
|
| PubChem CID |
5283137
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
582.5±50.0 °C at 760 mmHg
|
| Flash Point |
199.7±23.6 °C
|
| Vapour Pressure |
0.0±3.7 mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
2.09
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
26
|
| Complexity |
448
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CCCCC[C@@H](/C=C/[C@@H]1[C@H]([C@H](CC(O1)O)O)C/C=C\CCCC(=O)O)O
|
| InChi Key |
XNRNNGPBEPRNAR-JQBLCGNGSA-N
|
| InChi Code |
InChI=1S/C20H34O6/c1-2-3-6-9-15(21)12-13-18-16(17(22)14-20(25)26-18)10-7-4-5-8-11-19(23)24/h4,7,12-13,15-18,20-22,25H,2-3,5-6,8-11,14H2,1H3,(H,23,24)/b7-4-,13-12+/t15-,16-,17-,18+,20?/m0/s1
|
| Chemical Name |
(Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]oxan-3-yl]hept-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6992 mL | 13.4960 mL | 26.9920 mL | |
| 5 mM | 0.5398 mL | 2.6992 mL | 5.3984 mL | |
| 10 mM | 0.2699 mL | 1.3496 mL | 2.6992 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA